Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 20, Issue 41, 2014, Pages 15018-15027

  Murata, Miki ^a   Yoshida, Katsunori ^a   Yamaguchi, Takashi ^a   Matsuzaki, Koichi ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Chronic viral hepatitis; Fibro carcinogenesis; Hepatocellular carcinoma; Phosphorylation; Smad3; Transforming growth factor

Indexed keywords

SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; SMAD3 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CANCER INHIBITION; CANCER RISK; CHRONIC HEPATITIS; CHRONIC INFLAMMATION; CHRONIC LIVER DISEASE; DISEASE COURSE; HEPATITIS VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VIRUS HEPATITIS; ANIMAL; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPLICATION; LIVER; LIVER TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RISK ASSESSMENT; RISK FACTOR; VIROLOGY; VIRUS CELL TRANSFORMATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, VIRAL; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER; LIVER NEOPLASMS; PHOSPHORYLATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84912140790     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i41.15018     Document Type: Article

References (76)

1. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005; 23: 2892-2899 [PMID: 15860847 DOI: 10.1200/JCO.2005.03.196]
2. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129 [PMID: 15014185 DOI: 10.1056/NEJMra031087]
3. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305 [PMID: 10681285 DOI: 10.7326/0003-4819-132-4-200002150-00008]
4. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466 [PMID: 7739682 DOI: 10.1056/NEJM199506013322202]
5. Moses HL, Yang EY, Pietenpol JA. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990; 63: 245-247 [PMID: 2208284]
6. Roberts AB, Sporn MB. The transforming growth factor-βs. In: Sporn MB, Roberts AB, editors. Peptide Growth Factors and Their Receptors. Berlin: Springer, 1990: 419-472
7. Bellam N, Pasche B. Tgf-beta signaling alterations and colon cancer. Cancer Treat Res 2010; 155: 85-103 [PMID: 20517689 DOI: 10.1007/978-1-4419-6033-7-5]
8. Matsuzaki K. Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells. Cell Tissue Res 2012; 347: 225-243 [PMID: 21626291 DOI: 10.1007/s00441-011-1178-6]
9. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-471 [PMID: 9393997 DOI: 10.1038/37284]
10. Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700 [PMID: 12809600]
11. Wrana JL. Regulation of Smad activity. Cell 2000; 100: 189-192 [PMID: 10660041]
12. Kretzschmar M, Doody J, Timokhina I, Massagué J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev 1999; 13: 804-816 [PMID: 10197981]
13. Mori S, Matsuzaki K, Yoshida K, Furukawa F, Tahashi Y, Yamagata H, Sekimoto G, Seki T, Matsui H, Nishizawa M, Fujisawa J, Okazaki K. TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 2004; 23: 7416-7429 [PMID: 15326485 DOI: 10.1038/sj.onc.1207981]
14. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004; 430: 226-231 [PMID: 15241418 DOI: 10.1038/nature02650]
15. Kamaraju AK, Roberts AB. Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factorbeta- mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J Biol Chem 2005; 280: 1024-1036 [PMID: 15520018 DOI: 10.1074/jbc.M403960200]
16. Sekimoto G, Matsuzaki K, Yoshida K, Mori S, Murata M, Seki T, Matsui H, Fujisawa J, Okazaki K. Reversible Smaddependent signaling between tumor suppression and oncogenesis. Cancer Res 2007; 67: 5090-5096 [PMID: 17545585 DOI: 10.1158/0008-5472.CAN-06-4629]
17. Matsuzaki K, Kitano C, Murata M, Sekimoto G, Yoshida K, Uemura Y, Seki T, Taketani S, Fujisawa J, Okazaki K. Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer. Cancer Res 2009; 69: 5321-5330 [PMID: 19531654 DOI: 10.1158/0008-5472.CAN-08-4203]
18. Matsuzaki K. Smad phospho-isoforms direct context-dependent TGF-β signaling. Cytokine Growth Factor Rev 2013; 24: 385-399 [PMID: 23871609 DOI: 10.1016/j.cytogfr.2013.06.002]
19. Massagué J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005; 19: 2783-2810 [PMID: 16322555 DOI: 10.1101/gad.1350705]
20. Cohen MM. TGF beta/Smad signaling system and its pathologic correlates. Am J Med Genet A 2003; 116A: 1-10 [PMID: 12476444 DOI: 10.1002/ajmg.a.10750]
21. Bissell DM. Chronic liver injury, TGF-beta, and cancer. Exp Mol Med 2001; 33: 179-190 [PMID: 11795478 DOI: 10.1038/emm.2001.31]
22. Inagaki Y, Okazaki I. Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 2007; 56: 284-292 [PMID: 17303605 DOI: 10.1136/gut.2005.088690]
23. Zavadil J, Bitzer M, Liang D, Yang YC, Massimi A, Kneitz S, Piek E, Bottinger EP. Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc Natl Acad Sci USA 2001; 98: 6686-6691 [PMID: 11390996 DOI: 10.1073/pnas.111614398]
24. Bissell DM, Roulot D, George J. Transforming growth factor beta and the liver. Hepatology 2001; 34: 859-867 [PMID: 11679955]
25. Massagué J. TGFbeta in Cancer. Cell 2008; 134: 215-230 [PMID: 18662538 DOI: 10.1016/j.cell.2008.07.001]
26. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638 [PMID: 12711737 DOI: 10.1056/NEJMoa021423]
27. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208 [PMID: 20141834 DOI: 10.1016/j.cell.2009.12.052]
28. Tsutsumi T, Suzuki T, Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Matsuura Y, Kimura S, Koike K, Miyamura T. Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology 2002; 304: 415-424 [PMID: 12504580 DOI: 10.1006/viro.2002.1702]
29. Derynck R, Miyazono K. The TGF-β signaling. New York: Cold Spring Harbor Laboratory Press, 2008
30. Wicks SJ, Lui S, Abdel-Wahab N, Mason RM, Chantry A. Inactivation of smad-transforming growth factor beta signaling by Ca(2+)-calmodulin-dependent protein kinase II. Mol Cell Biol 2000; 20: 8103-8111 [PMID: 11027280 DOI: 10.1128/MCB.20.21.8103-8111.2000]
31. Furukawa F, Matsuzaki K, Mori S, Tahashi Y, Yoshida K, Sugano Y, Yamagata H, Matsushita M, Seki T, Inagaki Y, Nishizawa M, Fujisawa J, Inoue K. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 2003; 38: 879-889 [PMID: 14512875]
32. Ho J, Cocolakis E, Dumas VM, Posner BI, Laporte SA, Lebrun JJ. The G protein-coupled receptor kinase-2 is a TGFbeta- inducible antagonist of TGFbeta signal transduction. EMBO J 2005; 24: 3247-3258 [PMID: 16121194 DOI: 10.1038/sj.emboj.7600794]
33. Liu F. Smad3 phosphorylation by cyclin-dependent kinases. Cytokine Growth Factor Rev 2006; 17: 9-17 [PMID: 16289004 DOI: 10.1016/j.cytogfr.2005.09.010]
34. Millet C, Yamashita M, Heller M, Yu LR, Veenstra TD, Zhang YE. A negative feedback control of transforming growth factor-beta signaling by glycogen synthase kinase 3-mediated Smad3 linker phosphorylation at Ser-204. J Biol Chem 2009; 284: 19808-19816 [PMID: 19458083 DOI: 10.1074/jbc.M109.016667]
35. Alarcón C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, Barlas A, Miller AN, Manova-Todorova K, Macias MJ, Sapkota G, Pan D, Massagué J. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGFbeta pathways. Cell 2009; 139: 757-769 [PMID: 19914168 DOI: 10.1016/j.cell.2009.09.035]
36. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511 [PMID: 15229469 DOI: 10.1038/nri1391]
37. Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, Lee KY, Bussey C, Steckel M, Tanaka N, Yamada G, Akira S, Matsumoto K, Ghosh S. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 2005; 19: 2668-2681 [PMID: 16260493 DOI: 10.1101/gad.1360605]
38. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009; 19: 156-172 [PMID: 19153598 DOI: 10.1038/cr.2009.5]
39. Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol 2007; 9: 1000-1004 [PMID: 17762890 DOI: 10.1038/ncb434]
40. Frederick JP, Liberati NT, Waddell DS, Shi Y, Wang XF. Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol Cell Biol 2004; 24: 2546-2559 [PMID: 14993291 DOI: 10.1128/MCB.24.6.2546-2559.2004]
41. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994; 371: 257-261 [PMID: 8078588 DOI: 10.1038/371257a0]
42. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995; 92: 5545-5549 [PMID: 7777546]
43. Yang YA, Zhang GM, Feigenbaum L, Zhang YE. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell 2006; 9: 445-457 [PMID: 16766264 DOI: 10.1016/j.ccr.2006.04.025]
44. Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, Kaibori M, Kamiyama Y, Nishizawa M, Fujisawa J, Okazaki K, Seki T. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007; 46: 48-57 [PMID: 17596875 DOI: 10.1002/hep.21672]
45. Murata M, Matsuzaki K, Yoshida K, Sekimoto G, Tahashi Y, Mori S, Uemura Y, Sakaida N, Fujisawa J, Seki T, Kobayashi K, Yokote K, Koike K, Okazaki K. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology 2009; 49: 1203-1217 [PMID: 19263472 DOI: 10.1002/hep.22765]
46. Nagata H, Hatano E, Tada M, Murata M, Kitamura K, Asechi H, Narita M, Yanagida A, Tamaki N, Yagi S, Ikai I, Matsuzaki K, Uemoto S. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor- suppression in rat hepatocellular carcinoma. Hepatology 2009; 49: 1944-1953 [PMID: 19418558 DOI: 10.1002/hep.22860]
47. Date M, Matsuzaki K, Matsushita M, Tahashi Y, Sakitani K, Inoue K. Differential regulation of activin A for hepatocyte growth and fibronectin synthesis in rat liver injury. J Hepatol 2000; 32: 251-260 [PMID: 10707865]
48. Matsuzaki K. Smad3 phosphoisoform-mediated signaling during sporadic human colorectal carcinogenesis. Histol Histopathol 2006; 21: 645-662 [PMID: 16528675]
49. Kawamata S, Matsuzaki K, Murata M, Seki T, Matsuoka K, Iwao Y, Hibi T, Okazaki K. Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis. Inflamm Bowel Dis 2011; 17: 683-695 [PMID: 20602465 DOI: 10.1002/ibd.21395]
50. Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 2009; 44 Suppl 19: 96-101 [PMID: 19148801 DOI: 10.1007/s00535-008-2258-6]
51. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061]
52. Manno M, Cammà C, Schepis F, Bassi F, Gelmini R, Giannini F, Miselli F, Grottola A, Ferretti I, Vecchi C, De Palma M, Villa E. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004; 127: 756-763 [PMID: 15362032 DOI: 10.1053/j.gastro.2004.06.021]
53. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-1956 [PMID: 2834034]
54. Okuno M, Kojima S, Akita K, Matsushima-Nishiwaki R, Adachi S, Sano T, Takano Y, Takai K, Obora A, Yasuda I, Shiratori Y, Okano Y, Shimada J, Suzuki Y, Muto Y, Moriwaki Y. Retinoids in liver fibrosis and cancer. Front Biosci 2002; 7: d204-d218 [PMID: 11779708]
55. Friedman SL, Arthur MJ. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest 1989; 84: 1780-1785 [PMID: 2556445]
56. Pinzani M, Milani S, Herbst H, DeFranco R, Grappone C, Gentilini A, Caligiuri A, Pellegrini G, Ngo DV, Romanelli RG, Gentilini P. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol 1996; 148: 785-800 [PMID: 8774134]
57. Tahashi Y, Matsuzaki K, Date M, Yoshida K, Furukawa F, Sugano Y, Matsushita M, Himeno Y, Inagaki Y, Inoue K. Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology 2002; 35: 49-61 [PMID: 11786959]
58. Pinzani M, Macias-Barragan J. Update on the pathophysiology of liver fibrosis. Expert Rev Gastroenterol Hepatol 2010; 4: 459-472 [PMID: 20678019 DOI: 10.1586/egh.10.47]
59. Yoshida K, Matsuzaki K, Mori S, Tahashi Y, Yamagata H, Furukawa F, Seki T, Nishizawa M, Fujisawa J, Okazaki K. Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol 2005; 166: 1029-1039 [PMID: 15793284 DOI: 10.1016/S0002-9440(10)62324-3]
60. Kluwe J, Pradere JP, Gwak GY, Mencin A, De Minicis S, Osterreicher CH, Colmenero J, Bataller R, Schwabe RF. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 2010; 138: 347-359 [PMID: 19782079 DOI: 10.1053/j.gastro.2009.09.015]
61. Webber EM, Wu JC, Wang L, Merlino G, Fausto N. Overexpression of transforming growth factor-alpha causes liver enlargement and increased hepatocyte proliferation in transgenic mice. Am J Pathol 1994; 145: 398-408 [PMID: 8053497]
62. Nishida N, Nishimura T, Ito T, Komeda T, Fukuda Y, Nakao K. Chromosomal instability and human hepatocarcinogenesis. Histol Histopathol 2003; 18: 897-909 [PMID: 12792902]
63. Tsai JF, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY, Tsai JH. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 1997; 76: 968-974 [PMID: 9328161]
64. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-1213 [PMID: 12395331 DOI: 10.1053/jhep.2002.36780]
65. Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 2000; 45: 1944-1948 [PMID: 11117564]
66. Shibuya A, Tanaka K, Miyakawa H, Shibata M, Takatori M, Sekiyama K, Hashimoto N, Amaki S, Komatsu T, Morizane T. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology 2002; 35: 1172-1178 [PMID: 11981767]
67. But DY, Lai CL, Yuen MF. Natural history of hepatitisrelated hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1652-1656 [PMID: 18350595 DOI: 10.3748/wjg.14.1652]
68. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouzé E, Calvo F, Zucman-Rossi J. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44: 694-698 [PMID: 22561517 DOI: 10.1038/ng.2256]
69. Matsuzaki K. Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis 2011; 32: 1578-1588 [PMID: 21798854 DOI: 10.1093/carcin/bgr172]
70. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25: 143-154 [PMID: 15918143 DOI: 10.1055/s-2005-871194]
71. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174 [PMID: 12124405 DOI: 10.1056/NEJMoa013215]
72. Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, Sung JJ. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-1498 [PMID: 15361502 DOI: 10.1136/gut.2003.033324]
73. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218 DOI: 10.1001/jama.295.1.65]
74. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526 [PMID: 12883497 DOI: 10.1053/jhep.2003.50346]
75. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346 [PMID: 12149612 DOI: 10.1038/ng0802-339]
76. Yamaguchi T, Matsuzaki K, Inokuchi R, Kawamura R, Yoshida K, Murata M, Fujisawa J, Fukushima N, Sata M, Kage M, Nakashima O, Tamori A, Kawada N, Tsuneyama K, Dooley S, Seki T, Okazaki K. Phosphorylated Smad2 and Smad3 signaling: Shifting between tumor suppression and fibro-carcinogenesis in chronic hepatitis C. Hepatol Res 2013; 43: 1327-1342 [PMID: 23458062 DOI: 10.1111/hepr.12082]